Arizona's Off-Label Promotion Law May Hinge On Gottlieb

By Alexis Kellert, Weil Gotshal & Manges LLP (May 8, 2017, 3:54 PM EDT) -- In November, the U.S. Food and Drug Administration announced its decision to collect feedback regarding whether drug and device manufacturers should be allowed to promote their products for uses outside of their FDA-approved treatments (i.e., "off-label").[1] The mere fact that the FDA sought this type of public input on the issue marked a significant shift in the agency's enforcement regime, which has prohibited off-label advertising since the mid-1960s....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!